News List

The first c-Met inhibitor approved by the FDA to market

On May 6, the FDA approved the listing of Novartis Tabrecta (capmatinib) for the treatment of patients with locally adva

The cortisol synthesis inhibitor Isturia developed by Recordati has been approved by the European Union!

On January 16, 2020, the Italian pharmaceutical company Recordati recently announced that the European Commission (EC) h

Fapilavir completes clinical research and shows good clinical efficacy

On March 17th, the State Council's joint prevention and control mechanism held a press conference on the latest rese

Migraine relieved within 1 hour, FDA approves new oral medication

2020.02.27, Biohaven announced that the US FDA has approved the company's CGRP receptor inhibitor Nurtec (rimegepant

Insomnia and schizophrenia innovative treatments approved

Dayvigo (lembroexant) developed by Eisai is an orexin receptor antagonist. Orexin is a neuropeptide secreted by the hypo

First oral small molecule CGRP receptor inhibitor approved today for the treatment of migraine

Recently, the US FDA announced that it has approved the listing of the calcitonin gene-related peptide (CGRP) receptor a

Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma

Novartis recently announced topline results from its pivotal global Phase III LUSTER-11and LUSTER-22studies that explore

Roche T + A immunotherapy research achieves historic breakthrough

November 22, 2019, Roche announces data from positive studies of the IMbrave 150 phase III clinical trial aimed at treat

Hansoh pharm's first sorts of new medicine "Flumatinib" will be approved for listing

Flumatinib is a tyrosine kinase inhibitor and it’s a second-generation TK inhibitor drug against Bcr-Abl that is intende

FDA approves Lilly Reyvow

Recently, Lilly announced that the US FDA approved the company's development of Reyvow (lasmiditan) tablets, as a tr